盐酸纳美芬(Nalmefene Hydrochloride) - 药物靶点：Opioid receptors_在研适应症：酗酒，阿片类药物过量，瘙痒_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Intranasal nalmefene - Opiant Pharmaceuticals、nalmefene、Nalmefene hydrochloride dihydrate

+ [31]

靶点

Opioid receptors

作用方式

拮抗剂

作用机制

Opioid receptors拮抗剂(阿片样受体拮抗剂)

治疗领域

其他疾病皮肤和肌肉骨骼疾病

在研适应症

酗酒阿片类药物过量瘙痒+ [1]

非在研适应症

病理性赌博症尼古丁成瘾

原研机构

Baxter International, Inc.

在研机构

Canton Strategic Holdings, Inc.

Avior Bio, Inc.

H. Lundbeck A/S

+ [6]

非在研机构

Somaxon Pharmaceuticals, Inc.Hikma Pharmaceuticals USA, Inc.

Opiant Pharmaceuticals, Inc.

权益机构

Biotie Therapies Corp.

Somaxon Pharmaceuticals, Inc.

H. Lundbeck A/S

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (1995-04-17),

阿片类药物过量

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、优先审评 (美国)

登录后查看时间轴

结构/序列

分子式C21H26ClNO3

InChIKeyGYWMRGWFQPSQLK-OPHZJPRHSA-N

CAS号58895-64-0

关联

66

项与盐酸纳美芬相关的临床试验

NCT06733519

/ Not yet recruiting临床2期

Evaluation of TH104 for Moderate to Severe Pruritus in Primary Biliary Cholangitis: a Double-blind, Randomized, Placebo-controlled, Phase 2a Study

A phase 2a, multicenter, randomized, double-blind, placebo-controlled study of TH104 in primary biliary cholangitis (PBC) participants with moderate to severe pruritus.

开始日期2026-06-01

申办/合作机构

Canton Strategic Holdings, Inc.

ChiCTR2500114019

/ RecruitingN/AIIT

The Effect of Nalmefene on Postoperative Gastrointestinal Function Recovery: A Prospective Randomized Controlled Study

开始日期2025-05-26

申办/合作机构-

ChiCTR2500111207

/ CompletedN/AIIT

50% Efficacy Dose of Intravenous Nalmefene in Suppressing Sufentanil-Induced Cough in Preschool Children

开始日期2025-03-01

申办/合作机构

首都医科大学附属北京儿童医院

100 项与盐酸纳美芬相关的临床结果

登录后查看更多信息

100 项与盐酸纳美芬相关的转化医学

登录后查看更多信息

100 项与盐酸纳美芬相关的专利（医药）

登录后查看更多信息

537

项与盐酸纳美芬相关的文献（医药）

2026-01-14·ALCOHOL AND ALCOHOLISM

Initiation of pharmacotherapy for alcohol use disorder in Japan: a longitudinal descriptive study

Article

作者: Nakagami, Yukako ; Fukasawa, Toshiki ; Kawakami, Koji ; Kitamura, Misato ; Shirakawa, Sachiyo

Abstract:

Background:

Alcohol use disorder (AUD) is common worldwide, but the proportion of patients receiving pharmacotherapy remains low. In Japan, patterns of pharmacotherapy initiation for AUD have not been fully characterized. Here, we quantified the cumulative incidence of pharmacotherapy initiation among patients newly diagnosed with AUD in Japan.

Methods:

We conducted a descriptive study using a Japanese insurance claims database. We created annual cohorts of adults aged 20–64 years who were newly diagnosed with AUD during fiscal years (FYs) 2012–21. Cumulative incidence for pharmacotherapy initiation was estimated, with death treated as a competing risk.

Results:

The study included 13 936 patients. Across FY 2012–21 cohorts, mean age was 43.3–44.8 years and men accounted for 72.6%–79.3% of each cohort. At cohort entry (Day 0), the cumulative incidence of pharmacotherapy initiation rose from 18.0% in FY 2012 to 35.2% in FY 2021. The 1-year corresponding cumulative incidences were 28.1% and 44.9%, respectively. Market approval of acamprosate (FY 2013) and nalmefene (FY 2018) and the publication of Japan’s AUD treatment guideline (FY 2018) were each followed by marked year-on-year increases in pharmacotherapy initiation.

Conclusions:

Although the observed incidence may have been inflated by Japan’s reimbursement policy, which requires an AUD diagnosis before medication can be prescribed, pharmacotherapy initiation exceeded that reported in other countries and has increased steadily since FY 2012. Introduction of new drugs and guideline dissemination appear to have accelerated treatment initiation and substantially altered treatment practice. These findings can help clinicians and policy-makers close the persistent treatment gap.

2026-01-01·MOLECULAR AND CELLULAR ENDOCRINOLOGY

Interrelationship between alcohol consumption, overnutrition, and pharmacotherapy for liver steatosis: Considerations and proposals

Review

作者: Zúñiga-Hernández, Jessica ; Videla, Luis A ; Valenzuela, Rodrigo ; Farías, Camila ; Muñoz, Yasna

Alcoholism and overnutrition both contribute to the development of hepatic steatosis in humans. In alcoholic liver disease, steatosis is driven by (i) alcohol oxidation via alcohol dehydrogenase (ADH), which increases the NADH/NAD⁺ ratio, and (ii) induction of cytochrome P450 2E1 (CYP2E1), which elevates oxidative stress. Both pathways generate toxic acetaldehyde. Overnutrition is characterized by excessive energy intake, high consumption of refined carbohydrates and saturated fatty acids (FAs), and low intake of dietary fiber, fruits, vegetables, and n-3 polyunsaturated fatty acids (n-3 PUFAs). The increased NADH/NAD⁺ ratio inhibits the Krebs cycle and FA β-oxidation, redirecting acetyl-CoA toward de novo lipogenesis. This process is mainly regulated by insulin-mediated activation of sterol regulatory element-binding protein-1c (SREBP-1c) and suppression of peroxisome proliferator-activated receptor-α (PPAR-α) related to n-3 PUFA depletion, which further impairs FA β-oxidation and upregulates citrate carrier expression, promoting lipogenesis. Chronic exposure to either alcohol or overnutrition independently promotes steatosis; however, co-exposure significantly exacerbates the condition, as shown in emerging preclinical studies. In humans, the relationship remains complex and inconsistent. Several anti-steatotic agents have been explored, including n-3 PUFAs, vitamins (E, C, D), polyphenols (curcumin, resveratrol, anthocyanins), anti-craving medications (disulfiram, naltrexone, nalmefene, acamprosate), and appetite suppressants (e.g., topiramate), as well as combination therapies such as naltrexone with bupropion. Despite the range of available interventions, inconsistent outcomes in past clinical trials hinder the establishment of standardized protocols. This underscores the urgent need to investigate synergistic effects of combined risk factors to better guide therapeutic strategies for hepatic steatosis prevention and reversal, and inform the health professionals on these aspects.

2026-01-01·INTERNAL MEDICINE

A Prospective Observational Study of AUDIT-Based Risk Stratification and Drinking Guidance Provided by Hepatologists in Patients with Alcoholic Liver Disease

Article

作者: Dezumi, Reina ; Kusano, Chika ; Nomura, Nao ; Hidaka, Hisashi ; Uojima, Haruki ; Asakura, Takahumi ; Tanaka, Yasuhito ; Sawayama, Enami ; Inada, Ken ; Iwasaki, Shuichiro ; Iida, Junki

Objectives Alcoholic liver disease is the leading cause of cirrhosis and liver failure in Japan. We assessed hepatologist-led interventions stratified using the alcohol use disorder identification test. Methods This was a single-center, prospective study. Outcomes included total alcohol consumption, number of heavy drinking days, drinking risk level, and liver function over 24 weeks. Patients Patients with chronic liver disease were stratified into three groups according to alcohol use disorder identification test scores: <10 (education only), 10-19 (hepatologist-led intervention), and ≥20 (psychiatric referral). Patients in the hepatologist-led group received drinking guidance, psychosocial support, and nalmefene, when indicated. Results Between August 2022 and September 2025, 932 patients were screened; 823, 78, and 31 had alcohol use disorder identification test scores of <10, 10-19, and ≥20 points, respectively. Of the 78 patients in the hepatologist-led intervention group, 74 completed follow-up. In this group, median total alcohol consumption decreased from 63.1 to 35.1 g/day (p=0.001) and heavy-drinking days from 17.0 to 11.3 days/month (p=0.002). Drinking risk level downstaging was achieved in 52 patients (70.2%), who showed significant improvements in aspartate aminotransferase (p=0.027) and γ-GTP (p=0.014) levels and experienced fewer cirrhosis-related complications in comparison to patients without downstaging. Logistic regression identified baseline hepatocellular carcinoma as an independent predictor of drinking risk-level downstaging (odds ratio, 5.23; 95% confidence interval, 1.10-15.3). Conclusions Hepatologist-led alcohol use disorder identification test-based management of alcoholic liver disease reduces alcohol intake. Drinking risk-level downstaging has been linked to improved liver biochemistry and clinical outcomes, offering a practical strategy in which psychiatric resources are limited.

247

项与盐酸纳美芬相关的新闻（医药）

2026-01-28

·PRNewswire

Elysium Therapeutics Raises $7.5 Million SAFE Round to Accelerate Development of Novel Rescue Therapy Designed to Specifically Combat Oral Fentanyl Overdose

LYONS, Colo., Jan. 28, 2026 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to prevent and reverse overdoses caused by highly potent, synthetic opioids especially when ingested orally, today announced that it has completed a $7.5 million SAFE round. Elysium intends to accelerate development of its SOOPR™ (Synthetic Opioid Overdose Protection and Reversal) technology designed specifically as a rescue treatment for overdoses brought on by synthetic opioids, including fentanyl and the emerging threat of more potent nitazenes. "With these funds in place, we have initiated work to progress our SOOPR technology through preclinical and clinical studies as we develop this important, life-saving technology to address the deadly overdose epidemic caused by illicit synthetic opioids," said Greg Sturmer, CEO of Elysium Therapeutics. "Our society continues to see far too many overdose fatalities, and we believe that our SOOPR technology has enormous potential to become the new standard for rescue and as a countermeasure as the illicit drug market evolves to progressively more dangerous opioids." SOOPR is a rapid-onset, long-acting rescue agent specifically designed to prevent and reverse overdoses from synthetic opioids, including oral fentanyl and nitazenes. SOOPR utilizes a proprietary naloxone prodrug formulation that offers more rapid onset and longer duration of action than current rescue agents (e.g., NARCAN, Kloxxado, Opvee). The technology is designed to rapidly restore respiration, reducing the risk of hypoxic brain injury and death, and provide 12 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization. Further, SOOPR delivers naloxone with a unique, infusion-like pharmacokinetic profile that is ideally suited to reduce the risk of severe withdrawal symptoms commonly associated with nalmefene and high-dose naloxone products. SOOPR is also intended to prevent same-day re-use of opioids and to offer an essential period for family members and healthcare professionals to assist the overdose patient in accessing medically-assisted therapy, which represents their best opportunity for long-term survival. Data from in vivo proof-of-concept studies of SOOPR demonstrated a more rapid onset of action versus intranasal and intramuscular naloxone and a significantly longer duration of action. This profile is specifically designed to counteract oral fentanyl and nitazene overdoses associated with prolonged exposures that often outlast the short-acting profile of existing rescue agents. About Elysium Therapeutics Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl and nitazenes. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a fast-onset, long-acting opioid antagonist specifically designed to address oral synthetic opioid overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including NARCAN and Opvee. In addition, Elysium is also developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain, having achieved human proof-of-concept demonstrating a significant reduction in hydrocodone exposure in overdose scenarios versus generic hydrocodone. For more information, please visit . SOURCE Elysium Therapeutics 21% more press release views with Request a Demo

2026-01-21

·EINPresswire

REACX PHARMACEUTICALS NALMEFENE PHASE 1 CLINICAL STUDY

SOUTH SAN FRANCISCO, CA, UNITED STATES, January 21, 2026 / EINPresswire.com / -- ReacX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of long-term treatments for substance use disorders, today announced the initiation of a Phase I open-label, dose-escalation clinical study evaluating an investigational nalmefene implant. The Phase 1 clinical study is expected to enroll approximately 24 healthy adult volunteers. The primary objectives of the study are to characterize the pharmacokinetic release profile of the nalmefene implant, and to evaluate its safety and tolerability. The study is not designed to assess clinical efficacy. This clinical trial is supported by a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the HEAL Initiative (Helping to End Addiction Long-term ® Initiative). The first-in-human study initiates the clinical development of a six-month nalmefene implant using ReacX’s proprietary ProNeura ® long-term drug delivery technology, which is designed to provide continuous, controlled release of medication over extended periods. The investigational nalmefene implant is being developed as a potential relapse-prevention treatment following opioid detoxification. Nalmefene is an opioid receptor antagonist with established clinical use in injectable and nasal formulations for the acute reversal of opioid overdose. The long-acting subdermal implant formulation is intended to provide sustained opioid receptor blockade for six months. “Nalmefene has an established role in the acute management of opioid overdose, and the investigational nalmefene implant is being developed as a longer-term treatment to prevent relapse in opioid use following detoxification,” said Raj Patel, PhD, Chief Operating Officer of ReacX Pharmaceuticals and Principal Investigator of the NIDA Grant. “This Phase I study is focused on characterizing the pharmacokinetics of release, safety, and tolerability of nalmefene implants to support further clinical development.” The trial is being conducted under an Investigational New Drug (IND) application cleared by the U.S. Food and Drug Administration. Funding support from NIDA is provided as part of the NIH HEAL Initiative, a trans-agency effort to accelerate scientific solutions to the national opioid crisis. For more information about ReacX Pharmaceuticals, visit www.reacxpharma.com . Forward Looking Statements This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Any forward-looking statement peaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law. REACX PHARMACEUTICALS 833-824-0824 dleslie@reacxpharma.com rpatel@reacxpharma.com 400 Oyster Point Blvd, #326, South San Francisco, CA 94080 Rajesh Patel ReacX Pharmaceuticals, Inc +1 650-438-5769 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床1期

2026-01-13

·药通社

2025年，被毙最多的品种！

众所周知，2025年药监审评尺度明显加严。尤其进入下半年，化学仿制药药学及BE研究重大缺陷等系列文件发布，大批量受理号密集退审，一时间人人自危，不少申办方直接选择撤回重报。本号借此对2025年仿制药通知件进行了盘点，盘点结果显示：2025全年，累计共有551条一致性评价受理号被驳回，共涉及451家企业的302个仿制品种。其中驳回频次最高的几个品种，由高到低依次为（完整驳回表格见文末）：具体来看，2025年驳回TOP1品种：盐酸纳美芬注射液，共有17家失败。盐酸纳美芬注射液，一个理应豁免临床的真溶液，且已有海思科于去年12月首家过评，规格为1ml:0.1mg，但奇怪的是，在此之后却再无企业成功，反而连续17家驳回。经查，该产品原研已退市，目前参比为两家仿制企业，一家是美国普渡2mg/2ml，另一家是成都硕德1ml:0.1mg，成都硕德是成都苑东的子公司，然而苑东同样未能过评。更多分析详见：连续驳回15家，为何？ 2025年驳回TOP2品种：比拉斯汀片，共9家失败。比拉斯汀堪称2025年12月仿制申报的惨案了，片、口崩片、口服溶液一众被驳回，其中片剂9家，口服溶液5家，双双排上榜，这个品种行业已经默认是原料药问题，只能说未来选择需谨慎。更多分析详见：一天驳回7家，这个品种怎么了？ 2025年驳回TOP3品种：二甲硅油乳剂，共6家失败。二甲硅油乳剂，消泡剂，用以消除消化道内泡沫，属临床常用药。这一品种已有南京海纳和陕西丽彩成功仿制，但由于难度较高，仍有不少企业失败。但是注意到，目前尚在走审评流程的7家企业中，有2家都选择了和南京海纳合作，海纳已成功过评，拥有成功经验，与其合作确实是一种“快捷”方式。 ↓ 扫码加入药通社交流群 ↓ 上述几个品种仿制结果依旧惨烈，但也有品种情况好转。比如乙酰半胱氨酸注射液，这个品种是2024年驳回数量最多的，但由于早期申报的企业通知件都已下发，2025年的驳回数据终于没那么高了，也终于有企业仿制成功了，截至目前已有5家企业过评。相关内容：今年最卷的仿制药，又批了但值得注意的是，此品种原研赞邦已经在国内获批，适应症是祛痰，该适应症国内一直没有仿制企业获批。无论是好是坏，2025年已经结束，但相信这一年集中暴露的问题，也将无声地抬高仿制药的获批门槛。附：2025年一致性评价驳回情况汇总表 ↓⭐关注药通社，洞见行业趋势↓ 投稿/企业合作/内容沟通：药通社总编—华籍美人（Ww_150525） *添加请注明备注及来意

100 项与盐酸纳美芬相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02104	盐酸纳美芬	N07BB05	DB06230

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
酗酒	欧盟	H. Lundbeck A/S	2013-02-24
酗酒	冰岛	H. Lundbeck A/S	2013-02-24
酗酒	列支敦士登	H. Lundbeck A/S	2013-02-24
酗酒	挪威	H. Lundbeck A/S	2013-02-24
阿片类药物过量	美国	Hikma Pharmaceuticals USA, Inc.	1995-04-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
病理性赌博症	临床3期	-	Somaxon Pharmaceuticals, Inc.	2005-08-01
瘙痒	临床2期	-	Avior Bio, Inc.	2022-03-24
尼古丁成瘾	临床2期	美国	Somaxon Pharmaceuticals, Inc.	2005-09-01
阿片相关性障碍	临床1期	美国	Titan Pharmaceuticals, Inc.	2022-07-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04828005 (CTgov)	临床1期	-	84	Naloxone hydrochloride (Intranasal Naloxone)	簾積憲鬱獵鹹繭鹹繭遞(窪鬱遞網製鹹襯鹽願淵) = 鹽蓋簾憲簾築觸襯繭願鑰衊網廠壓壓夢鏇鏇糧 (窪顧糧網顧獵鹹膚鬱構, 0.6117) 更多	-	2025-07-14
				Nalmefene hydrochloride (Intranasal Nalmefene)	簾積憲鬱獵鹹繭鹹繭遞(窪鬱遞網製鹹襯鹽願淵) = 齋糧構鬱鹽觸壓願繭齋鑰衊網廠壓壓夢鏇鏇糧 (窪顧糧網顧獵鹹膚鬱構, 0.6240) 更多
NCT06719986 (CTgov)	临床1期	阿片类药物过量	24	Nalmefene HCl injection (Nalmefene Hydrochloride (HCl) Injection)	願願艱廠觸艱鹹廠鏇淵(鏇鏇餘夢窪艱積艱鹽築) = 鹽淵蓋鹽鬱窪醖繭醖憲鹹網獵齋鏇簾鏇餘顧選 (壓鹹窪觸製蓋鬱顧製鏇, 2.033) 更多	-	2025-07-03
				Naloxone HCl intranasal (Narcan Intranasal)	願願艱廠觸艱鹹廠鏇淵(鏇鏇餘夢窪艱積艱鹽築) = 齋餘觸遞壓觸鹽餘願膚鹹網獵齋鏇簾鏇餘顧選 (壓鹹窪觸製蓋鬱顧製鏇, 0.992) 更多
NCT06198686 (Company_Website) 人工标引	临床1期	瘙痒	12	TH104	衊選襯顧積醖選糧襯夢(構顧鹹構鏇壓襯積衊膚) = None 糧鬱構膚簾選鑰製遞鑰 (顧鹽選醖鏇範鏇築齋膚 )	积极	2024-11-18
NCT06198686 (Company_Website) 人工标引	临床1期	慢性肝病	12	TH104 (Child-Pugh A)	淵窪繭餘蓋鏇壓選膚艱(糧膚衊淵窪窪襯蓋鹹憲) = 鏇衊廠鹹衊選範遞選膚壓選艱艱襯鑰製夢壓夢 (構鬱衊齋鬱蓋願鹽簾窪 ) 更多	积极	2024-10-28
				TH104 (Child-Pugh B)	淵窪繭餘蓋鏇壓選膚艱(糧膚衊淵窪窪襯蓋鹹憲) = 網遞壓壓餘築憲糧壓鹽壓選艱艱襯鑰製夢壓夢 (構鬱衊齋鬱蓋願鹽簾窪 ) 更多
NCT04759768 (CTgov)	临床1期	-	68	Nalmefene Hydrochloride (Intranasal Nalmefene)	範齋膚築願鏇衊鏇衊艱(廠鹹願觸窪蓋襯遞糧淵) = 築齋選鬱夢廠醖蓋壓夢艱築醖醖餘鏇糧鹽艱鏇 (糧鏇襯廠膚築鹽醖蓋窪, 6.71) 更多	-	2024-08-13
				Nalmefene (Intramuscular Nalmefene)	範齋膚築願鏇衊鏇衊艱(廠鹹願觸窪蓋襯遞糧淵) = 鹽積膚衊窪齋網憲構夢艱築醖醖餘鏇糧鹽艱鏇 (糧鏇襯廠膚築鹽醖蓋窪, 1.18) 更多
NCT05219669 (CTgov)	临床1期	阿片类药物过量	24	Nalmefene Hydrochloride (Intranasal Nalmefene 1 Spray in 1 Nostril)	鹽顧遞鏇獵遞獵夢夢夢(壓積遞淵範鬱獵夢遞繭) = 艱鏇範觸餘鬱選餘網醖願製夢夢壓廠構餘範夢 (醖蓋獵襯選艱構鹽齋夢, 4.87) 更多	-	2024-08-05
				Nalmefene Hydrochloride (Intranasal Nalmefene 2 Sprays in 1 Nostril)	鹽顧遞鏇獵遞獵夢夢夢(壓積遞淵範鬱獵夢遞繭) = 鑰襯積襯淵選齋鹽簾壓願製夢夢壓廠構餘範夢 (醖蓋獵襯選艱構鹽齋夢, 11.2) 更多
Biospace 人工标引	临床1期	慢性肝病	12	TH104	鑰網醖網鹹窪憲選繭鬱(鏇蓋夢蓋廠鏇壓範製憲) = 襯簾鏇獵蓋鹽襯觸憲積襯鹽糧鹹鹽積齋顧夢簾 (製衊齋遞鑰齋鏇醖顧網 ) 更多	积极	2023-12-11
				TH104 (Child-Pugh A)	鑰網醖網鹹窪憲選繭鬱(鏇蓋夢蓋廠鏇壓範製憲) = 膚壓顧襯遞齋襯淵鏇餘襯鹽糧鹹鹽積齋顧夢簾 (製衊齋遞鑰齋鏇醖顧網 ) 更多
Biospace 人工标引	临床1期	胆汁淤积性瘙痒	-	TH104	範憲遞網範選糧衊齋鏇(窪製齋蓋積網獵餘積憲) = The Cmax and AUC0-∞ of TH104 was observed to be higher than the tablet product because of a possible reduced presystemic metabolism in the lower GI and liver, which is potentially advantageous for patients with an impaired liver. The half-life and Tmax was observed to be similar for both products. 選壓壓簾積壓鑰蓋願築 (願鏇淵膚選遞膚鑰鑰顧 ) 更多	积极	2023-11-27
NCT03096730 (CTgov)	N/A	疼痛 \| 麻醉 \| 痛觉过敏	150	Normal saline+Remifentanil (Normal Saline)	築窪憲鏇鑰艱築鑰糧觸(壓築鹽艱艱壓壓蓋壓鏇) = 鹽鑰選積繭夢構鹽製願齋構繭廠艱糧夢廠觸觸 (窪製鬱構廠蓋壓網齋觸, 6.0) 更多	-	2021-08-03
				Sufentanil+Normal saline (Sufentanil)	築窪憲鏇鑰艱築鑰糧觸(壓築鹽艱艱壓壓蓋壓鏇) = 簾膚積鑰遞觸艱顧衊顧齋構繭廠艱糧夢廠觸觸 (窪製鬱構廠蓋壓網齋觸, 23.40) 更多
NCT03278886 (PETER PAIN, CTgov)	临床1/2期	疼痛 \| 炎症 \| HIV感染 ... 更多	11	Low dose naltrexone (Low Dose Naltrexone)	構醖衊網糧構廠簾艱遞(鹽廠選膚醖選膚觸衊築) = 艱積遞廠壓廠衊衊願襯鏇網鹹遞衊蓋糧願淵餘 (鬱顧蓋簾壓廠積糧糧簾, 22.4) 更多	-	2020-08-03
				Nalmefene (Nalmefene)	構醖衊網糧構廠簾艱遞(鹽廠選膚醖選膚觸衊築) = 膚製醖簾鏇築醖網衊顧鏇網鹹遞衊蓋糧願淵餘 (鬱顧蓋簾壓廠積糧糧簾, NA) 更多